Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.
The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US.
Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta
Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis' Lucentis (ranibizumab) for leading causes of blindness, raising the prospect o
Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after getting FDA approval for first-in-class lung cancer therapy Exk
Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.